Trust Asset Management’s VeriSign VRSN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$233K Hold
927
0.01% 217
2026
Q1
$230K Hold
927
0.02% 212
2025
Q4
$225K Sell
927
-33
-3% -$8.29K 0.02% 213
2025
Q3
$268K Hold
960
0.02% 200
2025
Q2
$277K Hold
960
0.02% 191
2025
Q1
$244K Sell
960
-94
-9% -$21.4K 0.02% 195
2024
Q4
$218K Hold
1,054
0.02% 214
2024
Q3
$200K Buy
+1,054
New +$190K 0.02% 228
2024
Q1
Sell
-1,054
Closed -$217K 228
2023
Q4
$217K Hold
1,054
0.02% 197
2023
Q3
$213K Hold
1,054
0.02% 185
2023
Q2
$238K Hold
1,054
0.02% 182
2023
Q1
$223K Sell
1,054
-26
-2% -$5.36K 0.03% 182
2022
Q4
$222K Buy
+1,080
New +$207K 0.03% 185
2022
Q2
Sell
-992
Closed -$221K 201
2022
Q1
$221K Buy
992
+18
+2% +$3.93K 0.03% 185
2021
Q4
$247K Buy
+974
New +$225K 0.03% 183
2021
Q3
Sell
-912
Closed -$208K 203
2021
Q2
$208K Sell
912
-197
-18% -$42.9K 0.03% 183
2021
Q1
$220K Buy
1,109
+143
+15% +$28.1K 0.03% 171
2020
Q4
$209K Buy
+966
New +$198K 0.03% 150

Other funds holding VRSN

Trust Asset Management's VRSN Position: Q2 2026 in Review

Trust Asset Management held its VeriSign (VRSN) position steady in Q2 2026 at 927 shares worth $233K. The position accounts for 0.01% of the portfolio, ranked #217.

Trust Asset Management first reported a position in VRSN in Q4 2020 and has held it in 18 quarters since. The position peaked at $277K in Q2 2025. 126 funds tracked by Wall St. Rank hold VRSN as of Q2 2026.

  • Trust Asset Management held 927 shares of VeriSign worth $233K as of Q2 2026.
  • Trust Asset Management left its VeriSign share count unchanged in Q2 2026.
  • VeriSign made up 0.01% of Trust Asset Management's portfolio in Q2 2026, its #217 holding.
  • Trust Asset Management first reported a position in VeriSign in Q4 2020 and has held it in 18 quarters since.
  • Trust Asset Management's VeriSign position peaked at $277K in Q2 2025.
  • 126 funds tracked by Wall St. Rank held VeriSign as of Q2 2026.

Based on Trust Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.